# Olaparib

Source: https://nuclide.cc/drugs/olaparib/  
Nuclide record `olaparib` (Agent). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Olaparib was the first PARP inhibitor, and turned an inherited BRCA mutation from a risk factor into a drug target, including after surgery in breast cancer.

## Summary

Approved 2014 (ovarian), then maintenance first-line (SOLO-1, 7-year OS benefit), with bevacizumab (PAOLA-1, HRD+), metastatic BRCA breast (OlympiAD), adjuvant germline-BRCA HER2-negative early breast cancer (OlympiA, OS HR 0.72), pancreatic maintenance (POLO), and prostate (PROfound; PROpel with abiraterone). AstraZeneca/Merck.

## Fields

- Kind: Agent
- Status: approved
- Last checked: 2026-09-04
- Brand: Lynparza
- Modality: Small-molecule PARP inhibitor
- Mechanism: PARP1/2 inhibitor and trapper; synthetic lethality with HRD.
- Approvals: US 2014: gBRCA ovarian cancer ≥3 lines; US 2018: gBRCA HER2- metastatic breast cancer; US 2022: Adjuvant gBRCA high-risk HER2- early breast cancer
- Dosing: Oral; 300 mg twice daily; 1 year adjuvant (OlympiA); 2 years first-line ovarian maintenance; until progression otherwise
- Toxicity (grade 3+): Nausea 0.8%; Fatigue 1.8%; Anaemia 9%; Vomiting 0.7%; Diarrhoea 0.3%; Leukopenia 3%; Neutropenia 5%

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Olaparib
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Olaparib

## Connected records

- indications: [Metastatic castration-resistant prostate cancer](https://nuclide.cc/indications/prostate-mcrpc/), [Prostate cancer](https://nuclide.cc/indications/prostate/)
- targets: [PARP](https://nuclide.cc/targets/parp/)
- companies: [AstraZeneca](https://nuclide.cc/companies/astrazeneca/), [Merck & Co. (MSD)](https://nuclide.cc/companies/merck/)
- trials: [FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)](https://nuclide.cc/trials/nct06909825/)
- institutions: [The Royal Marsden](https://nuclide.cc/institutions/royal-marsden/)
- pathways: [Prostate cancer (KEGG map)](https://nuclide.cc/pathways/prostate-cancer-signalling/)
- ideas: [Adding a PARP inhibitor to PSMA radioligand therapy](https://nuclide.cc/ideas/idea-rlt-plus-parp-inhibitor/)
- pairings: [177Lu-PSMA-617 (Pluvicto) with olaparib](https://nuclide.cc/pairings/pluvicto-plus-olaparib/)

---
JSON: https://nuclide.cc/api/v1/entities/olaparib.json